Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 06, 2022

SELL
$1.36 - $1.88 $63,915 - $88,354
-46,997 Reduced 50.4%
46,249 $0
Q4 2021

Jan 19, 2022

BUY
$1.04 - $1.34 $96,975 - $124,949
93,246 New
93,246 $116,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Marquette Asset Management, LLC Portfolio

Follow Marquette Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marquette Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Marquette Asset Management, LLC with notifications on news.